

A-Share Listed Biological Products Companies - Profiles and Financial Data

<https://marketpublishers.com/r/A8ED02E6651EN.html>

Date: March 2017

Pages: 160

Price: US\$ 1,600.00 (Single User License)

ID: A8ED02E6651EN

Abstracts

In China, biological products include: bacterial vaccines (containing toxoid), viral vaccines, antitoxin and antiserum, blood products, cytokine, growth factors, enzyme, in vivo and in vitro diagnostic products, and other biological active preparations.

According to CRI, fast economic growth and residents' increasing income have pushed up people's medical expenses. China's biological products market outperforms the global average. In China, the market size exceeded CNY 130 billion in 2016, but its share in the pharmaceutical market was less than 10%, far below that in developed countries.

In the Thirteenth Five-Year Plan (2016-2020), biotechnological pharmaceuticals, new vaccines, new cell therapy preparations and other innovative pharmaceuticals were listed among the priorities of the biomedicine industry. It is expected that in the next few years, biotechnological advances and favorable policies will facilitate fast growth of the biological product industry.

In this report, CRI analyzes 38 biological products manufacturers listed in A-share market in China.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade (presently 2006 to 2016, we will update it to the latest as time goes by).

The operation status is demonstrated from the following perspectives: (1) financial indexes, such as earnings per share, book value per share (BPS), sales per share, net cash flow per share, return on net worth and debt to asset ratio; (2) indexes on the

income statement, such as revenue, operating profit, net profit and EBIT; (3) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (4) indexes on the balance sheet, such as liquid asset, fixed asset, current liability, non-current liability, capital reserve and shareholders' equity.

(1) Financial Indexes

Earnings per Share

Book Value per Share (BPS)

Sales per Share (SPS)

Net Cash Flow per Share from Operations

Net Cash Flow per Share (CNY)

Return on Net Worth

Net Profit Margin on Total Assets

Return on Invested Capital (ROIC) (%)

Gross Profit Margin on Sales (%)

Net Profit Margin on Sales (%)

EBIT Margin (%)

EBITDA Margin (%)

Debt to Asset Ratio (%)

Total Asset Turnover (times)

Cash/Operating Income Received from Sales of Goods or Services

YOY Growth Rate of Operating Revenue (%)

YOY Growth Rate of Operating Profit (%)

YOY Growth Rate of Net Profit Attributable to Shareholders of Parent Company (%)

(2) Summary of Income Statement

Gross Revenue (CNY, million)

Total Operating Costs (CNY, million)

Revenue (CNY, million)

Operating Profit (CNY, million)

Total Profit (CNY, million)

Net Profit (CNY, million)

Net Profit Attributable to Shareholders of Parent Company (CNY, million)

Non-recurring Items (CNY, million)

Net Profit Deducting Non-recurring Items (CNY, million)

R&D Costs (CNY, million)

Earnings Before Interest and Tax (EBIT) (CNY, million)

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (CNY, million)

(3) Summary of Balance Sheet

Liquid Asset (CNY, million)

Fixed Asset (CNY, million)

Long-term Equity Investment

Total Assets (CNY, million)

Liquid Liability (CNY, million)

Non-current Liability (CNY, million)

Total Liability (CNY, million)

Capital Reserve (CNY, million)

Surplus Reserve (CNY, million)

Undistributed Profit (CNY, million)

Shareholders' Equity (CNY, million)

Equity Attributable to Shareholders of Parent Company (CNY, million)

(4) Summary of Cash Flow Statement

Cash Received from Sales of Goods and Services (CNY, million)

Cash Flow from Operations (CNY, million)

Cash Paid to Purchase Fixed Assets, Intangible Assets and Other Long-term Assets (CNY, million)

Cash Paid for Investments (CNY, million)

Cash Flow from Investments (CNY, million)

Cash Received from Investors (CNY, million)

Cash Received from Borrowings (CNY, million)

Cash Flow from Financing (CNY, million)

Net Increase of Cash and Cash Equivalents (CNY, million)

Cash and Cash Equivalents, End of Period (CNY, million)

Depreciation and Amortization (CNY, million)

Contents

COMPANIES IN THE REPORT:

- 1 Ginwa Enterprise (Group) Inc. (600080.SH)
- 2 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
- 3 Shanghai Fosun Pharmaceutical Co., Ltd. (600196.SH)
- 4 Bluestar Adisseo Company (600299.SH)
- 5 Shanghai Jiaoda Onlly Co., Ltd. (600530.SH)
- 6 Zhongyuan Union Cell & Gene Engineering Corp., Ltd. (600645.SH)
- 7 Zhejiang Qianjiang Biochemical Co., Ltd. (600796.SH)
- 8 Tonghua Dongbao Pharmaceutical Co., Ltd. (600867.SH)
- 9 Autobio Diagnostics Co., Ltd. (603658.SH)
- 10 Wuhan Thalys Medical Technology Inc. (603716.SH)
- 11 Shenzhen Cau Technology Co., Ltd. (000004.SZ)
- 12 Shenzhen Neptunus Bioengineering Co., Ltd. (000078.SZ)
- 13 Zhenxing Biopharmaceutical & Chemical Inc. (000403.SZ)
- 14 Jiangsu Sihuan Bioengineering Co., Ltd. (000518.SZ)
- 15 Changchun High-Tech Industry Co., Ltd. (000661.SZ)
- 16 Hualan Biological Engineering Co., Ltd. (002007.SZ)
- 17 Shanghai Kehua Bio-engineering Co., Ltd. (002022.SZ)
- 18 DAAN Gene Co., Ltd. of Sun Yat-sen University (002030.SZ)
- 19 Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
- 20 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
- 21 Shandong Sinobioway Biomedicine Co., Ltd. (002581.SZ)
- 22 Changsheng Bio-technology Co., Ltd. (002680.SZ)
- 23 Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)
- 24 Chongqing Chifei Biological Products Co., Ltd. (300122.SZ)
- 25 Walvax Biotechnology Co., Ltd. (300142.SZ)
- 26 Staidson (Beijing) Biopharmaceuticals Co., Ltd. (300204.SZ)
- 27 Baotou Dongbao Bio-Tech Co., Ltd. (300239.SZ)
- 28 Beijing Leadman Biochemistry Co., Ltd. (300289.SZ)
- 29 Jiangxi Boya Bio-pharmaceutical Co., Ltd. (300294.SZ)
- 30 Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ)
- 31 Guangdong Vtr Bio-Tech Co., Ltd. (300381.SZ)
- 32 Beijing Strong Biotechnologies, Inc. (300406.SZ)
- 33 Fujian Cosunter Pharmaceutical Co., Ltd. (300436.SZ)
- 34 Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
- 35 Sichuan Maccura Biotechnology Co., Ltd. (300463.SZ)

- 36 Guangzhou Wondfo Biotech Co., Ltd. (300482.SZ)
- 37 Shandong Sino Biotechnology Co., Ltd. (300583.SZ)
- 38 Shenzhen Kangtai Biological Products Co., Ltd. (300601.SZ)

I would like to order

Product name: A-Share Listed Biological Products Companies - Profiles and Financial Data

Product link: <https://marketpublishers.com/r/A8ED02E6651EN.html>

Price: US\$ 1,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A8ED02E6651EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970